What Laverock Therapeutics does

Laverock Therapeutics is a UK-based, pre-clinical biotechnology company founded in 2021 as a spin-out from Tropic Biosciences, operating from King's Cross, London with R&D operations in Stevenage. The company develops programmable gene control technologies for advanced cell and gene therapies, anchored by its GEiGS (Gene Editing induced Gene Silencing) platform, which recodes endogenous microRNA genes to redirect their silencing activity toward new therapeutic targets with programmable, tunable, stable, and cell-state-specific activity. The integrated technology stack includes an automated, editing-agnostic Cell Engineering Platform, an Oxford Nanopore-based Rapid Genotyping Platform delivering sub-day turnaround with up to 20kb reads, and computational RNA Design capabilities.

Laverock applies this platform internally to a pre-clinical oncology pipeline led by two programs: LVK201, a T-cell / CAR-T program that simultaneously targets multiple immunomodulatory pathways and self-regulates CAR expression to mitigate exhaustion, and LVK301, a macrophage program designed to convert cold tumor microenvironments into hot ones through controlled delivery of immunomodulatory payloads. Beyond internal programs, the company offers tailored solutions across cell therapy, gene therapy, RNAi, and non-therapeutic applications including biomanufacturing and disease modeling.

Commercially, Laverock pursues a partnership and outlicensing model rather than product sales. Revenue, when generated, is expected to flow from platform licensing and outlicensing, collaborative development agreements (upfronts, milestones, royalties), and tailored-solution contract research. Business development is conducted through direct enterprise engagement with pharma and biotech, supported by an active conference presence at ESGCT, ARM Meeting on the Mesa, and BioEurope. The company is pre-revenue, funded to date by over £20M in seed capital led by Calculus Capital with Eli Lilly and other investors, plus more than £4M in non-dilutive UKRI/Innovate UK grants, and is preparing for a Series A in 2026.

Name

Laverock Therapeutics

Legal name

Laverock Therapeutics Ltd.

Website

https://laverocktx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Laverock Therapeutics is a UK pre-clinical biotechnology company developing programmable gene silencing technology (GEiGS) for advanced cell and gene therapies, serving pharmaceutical and biotech partners through licensing, co-development, and tailored solutions across oncology and genetic disease indications.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Platform Technology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

akta.pro secondary industries

Genome Editing Gene Therapies (CRISPR/TALEN/ZFN; in vivo/ex vivo) (HLAAACAD), Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD)

Keywords

• Gene silencing platform
• Cell therapy engineering
• Programmable gene control
• Therapeutic outlicensing
• Cell line engineering

Headquarters

HQ city

Stevenage

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Platform Licensing and Outlicensing: Laverock generates value through outlicensing its GEiGS technology platform and specific therapeutic programs to pharmaceutical and biotech partners. Partners gain access to programmable gene silencing capabilities for enhancing their own therapeutic pipelines.
2. Collaborative Development Partnerships: Co-development agreements where Laverock contributes its technology platforms to partnered programs, potentially including upfront payments, milestone payments, and royalties on resulting products.
3. Tailored Solutions and Contract Research: Non-exclusive partnerships providing access to Laverock's technology platforms for specific applications including biomanufacturing optimization, disease model generation, and programmed cell differentiation.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Laverock Therapeutics develops and licenses the GEiGS (Gene Editing induced Gene Silencing) platform, a programmable gene control technology that minimally edits endogenous microRNA genes to deliver tunable, stable, and specific gene silencing for advanced cell and gene therapies. The company supplements this core platform with automated cell engineering and rapid genotyping capabilities, applying them internally to T-cell (LVK201) and Macrophage (LVK301) oncology programs while making the platforms available to pharma and biotech partners through licensing, co-development, and tailored solution agreements.

Product overview

Laverock Therapeutics offers a suite of modular, unified technology platforms spanning the entire gene control workflow. The core GEiGS® (Gene Editing induced Gene Silencing) platform forms the foundation, supplemented by the Cell Engineering Platform for automated cell line development, the Rapid Genotyping Platform for high-fidelity sequencing, and RNA Design capabilities for computational silencing RNA design. The company applies these platforms internally to develop therapeutic programmes including T-cell therapeutics (LVK201) and macrophage therapeutics (LVK301) for oncology, while also offering tailored solutions for cell therapy, gene therapy, RNAi, and non-therapeutic applications including biomanufacturing and disease model generation.

Differentiator

Problem solved

Functional benefit

Products and services

• GEiGS (Gene Editing induced Gene Silencing) Platform Next-generation, programmable gene control platform that minimally edits endogenous non-coding genes to redirect naturally occurring microRNA silencing activity toward new therapeutic targets. Enables programmable, tunable, stable, specific, and multiplex gene silencing usable for cell therapy, gene therapy, RNAi applications, biomanufacturing, and disease modeling.
• Cell Engineering Platform Highly efficient, automated cell engineering platform agnostic to editing technology and cell type, delivering high-quality pooled and clonal cell lines with pooled and arrayed screening capabilities for functional characterization of engineered cells.
• Rapid Genotyping Platform (RGP) Integrated genotyping system based on Oxford Nanopore sequencing that delivers high-fidelity long-read sequencing for genotyping applications, with <1 day turnaround and up to 20kb read length, replacing complex Sanger/Illumina/long-read combination workflows at lower sample cost.
• T-Cell Therapeutics Programme (LVK201) CAR-T cell therapy program using GEiGS platform technology to improve anti-tumor activity without compromising safety, with self-regulating CAR expression to prevent T cell exhaustion and enable multiplex targeting of immunomodulatory pathways for solid tumor indications.
• Macrophage Therapeutics Programme (LVK301) Macrophage-based immunotherapy program using GEiGS platform to control macrophage cell phenotype and regulate delivery of immunomodulatory payloads, aimed at converting cold tumor microenvironments to hot states in solid tumor indications.

Quantifiable outcome

• Demonstrated improved solid tumor control by targeting three distinct immunomodulatory pathways simultaneously in ovarian cancer models
• +2 more outcomes

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core.

• ReNeuron Group LimitedcoreStrategic or Co-development Partner · 7 January 2026Collaboration to develop in-vivo gene therapy approaches combining Laverock's miRNA gene silencing platform with ReNeuron's CustomEX exosome-based precision delivery technology. The partnership aims to validate in-vivo gene targeting and unlock access to a broader spectrum of high-value therapeutic targets including those historically considered undruggable.
• Tropic BiosciencescoreOEM/ Whitelabel/ Licensing PartnerLaverock spun out from Tropic Biosciences with an exclusive license to the GEiGS gene silencing technology for human cell therapeutic applications. This licensing agreement is foundational to Laverock's business.
• UKRI (UK Research and Innovation)coreOthersUKRI, through Innovate UK, provides grant funding and innovation support including Biomedical Catalyst awards, SMART grants, and Investor Partnership funding totaling over £4M in non-dilutive capital.
• Innovate UKcoreOthersInnovate UK has awarded multiple grants to Laverock including £1M funding (2023), £0.5M Biomedical Catalyst award (2025), and over £2.2M in innovation grants (2026) to support platform development and therapeutic programs.

Scale indicators4 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Beam Therapeutics: Beam is a clinical-stage base editing company with a portfolio business model spanning in vivo and ex vivo programs, including engineered cell therapies — competing for the same partner attention and presenting an alternative 'programmable gene editing' wedge into cell therapy development.
• Cellectis: Cellectis develops allogeneic CAR-T cell therapies using TALEN-based gene editing and provides cell engineering platform services, directly overlapping Laverock's allogeneic / iPSC-derived cell therapy focus and offering partners a competing gene-edited cell therapy platform.
• Editas Medicine: Editas develops CRISPR-based genome editing medicines across in vivo gene editing and engineered cell therapies, including allogeneic CAR-T programs — comparable in platform business model and directly competitive in the gene-edited cell therapy space Laverock targets.
• Caribou Biosciences: Caribou is a clinical-stage gene editing company using CRISPR-Cas platforms to develop allogeneic CAR-T cell therapies, most directly competing with Laverock's LVK201 CAR-T program and sharing the same partner-seeking 'engineered cell platform' strategic posture.
• Arbor Biotechnologies: Arbor operates a discovery engine and partnered pipeline of next-generation gene editing tools, sharing Laverock's 'platform + partner' business model in genome editing with overlapping cell therapy and in vivo applications.
• Strand Therapeutics: Strand develops programmable, self-replicating mRNA systems designed to deliver controllable and tunable gene expression in cell therapy and oncology applications — conceptually the closest analog to Laverock's GEiGS 'right cell, right state, right level, right time' programmable gene control thesis, applied to engineered cell therapies rather than miRNA recoding.

Broad incumbents

• Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR-Cas9 gene editing company with multiple wholly-owned programs, representing a larger incumbent competitor in the gene editing space that limits partner appetite for pre-clinical platforms like GEiGS.
• Revvity (formerly Horizon Discovery): Revvity offers commercial gene editing tools, cell line engineering services, and cell therapy reagents used by partners doing exactly the kind of engineered cell work Laverock targets — competing indirectly as an established tools/services incumbent for cell therapy R&D budgets.

Emerging players

• Tome Biosciences: Tome is an emerging programmable gene editing platform company focused on 'integrase-mediated' precision genomic integration — operating in the same programmable gene editing category as GEiGS but with a different molecular mechanism, representing a next-generation competitive threat to programmable gene control platforms.

Others

• Tropic Biosciences: Tropic is the IP licensor of the GEiGS platform to Laverock and the spin-out parent; while their commercial focus is agricultural biotech, they share miRNA-recoding technology IP and a board seat (CEO Gilad Gershon) with Laverock, making them a structurally critical counterparty rather than a direct market competitor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laverock-tx

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laverock Therapeutics